Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: Evidence for synergism between serotonergic and noradrenergic reuptake inhibition

Neuropharmacology

Volumn 51, Issue 7-8, 2006, Pages 1172-1180

  Jones, Carrie K ^a   Eastwood, Brian J ^a   Need, Anne B ^a   Shannon, Harlan E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Carrageenan test; Duloxetine; Mixed serotonergic noradrenergic reuptake inhibition; Noradrenergic reuptake inhibition; Persistent pain; Serotonergic reuptake inhibition

Indexed keywords

CARRAGEENAN; DESIPRAMINE; DULOXETINE; FLUOXETINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIONISOXETINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; HYPERALGESIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANALGESICS, NON-NARCOTIC; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN CHEMISTRY; CARRAGEENAN; CYCLOHEXANOLS; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; EDEMA; FLUOXETINE; HEAT; HYPERALGESIA; MALE; NOREPINEPHRINE; PAROXETINE; PRESSURE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; THIOPHENES;

EID: 33750812245     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.08.005     Document Type: Article

References (37)

1. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., and Goldstein D.J. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 50 (2004) 2974-2984
2. Atkinson J.H., Slater M.A., Wahlgren D.R., Williams R.A., Zisook S., Pruitt S.D., Epping-Jordan J.E., Patterson T.l., Grant I., Abramson I., and Garfin S.R. Effects of noradrenergic and serotonergic antidepressants on chronic lower back pain intensity. Pain 83 (1999) 137-145
3. Bomholt S.F., Mikkelsen J.D., and Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48 (2005) 252-263
4. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., Shaw J.L., Thompson L., Nelson D.L., Hemrick-Leucke S.K., and Wong D.T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25 (2001) 871-880
5. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., and Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53 (1994) 55-63
6. Craig K.D. Emotional aspects of pain. In: Wall P.D., and Melzack R. (Eds). Textbook of Pain (1994), Churchill Livingstone, Edinburgh 261-274
7. DeLean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 235 (1978) E97-E102
8. Detke M.J., Lu Y., Goldstein D.J., McNamara R.K., and Demitrack M.A. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J. Psychiatric Res. 36 (2002) 383-390
9. Detke M.J., Wiltse C.G., Mallinckrodt C.H., McNamara R.K., and Demitrack M.A. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. 14 (2004) 457-470
10. Devor M., and Wall P.D. Reorganization of spinal cord sensory map after peripheral nerve injury. Nature 276 (1978) 75-76
11. Esser M.J., and Sawynok J. Acute amitriptyline in a rat model of neuropathic pain: differential symptoms and route effects. Pain 80 (1999) 643-653
12. Fields H.L., and Basbaum A.I. Central nervous system mechanisms of pain modulation. In: Wall P.D., and Melzack R. (Eds). Textbook of Pain (1994), Churchill Livingstone, Edinburgh 243-257
13. Fuller R.W., Hemrick-Luecke S.K., and Snoddy H.D. Effects of duloxetine, an antidepressant drug candidate, on concentrations of monoamines and their metabolites in rats and mice. J. Pharmacol. Exp. Ther. 269 (1994) 132-136
14. Gehlert D.R., Hemrick-Luecke S.K., Schober D.A., Krushinski J., Howbert J.J., Robertson D.W., Wong D.T., and Fuller R.W. (R)-thionisoxetine, a potent and selective inhibitor of central and peripheral norepinephrine uptake. Life Sci. 56 (1995) 1915-1920
15. Goldenberg D., Mayskiy M., Mossey C., Ruthazer R., and Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 39 (1996) 1852-1859
16. Goldstein D.J., Lu Y., Detke M.J., Lee T.C., and Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
17. Iyengar S., Webster A.A., Hemrick-Luecke S.K., Xu J.Y., and Simmons R.M. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J. Pharmacol. Exp. Ther. 311 (2004) 576-584
18. Jasmin L., Tien D., Janni G., and Ohara P.T. Is noradrenaline a significant factor in the analgesic effect of antidepressants?. Pain 106 (2003) 3-8
19. Jones S.L. Descending noradrenergic influences on pain. Prog. Brain Res. 88 (1991) 381-394
20. Jones C.K., Peters S.C., and Shannon H.E. Duloxetine, a selective serotonergic and noradrenergic reuptake inhibitor, is efficacious in persistent and inflammatory, but not acute nociceptive, pain states in rodents. J. Pharmacol. Exp. Ther. 312 (2005) 726-732
21. Kishore-Kumar R., Max M.B., Schafer S.C., Gaughan A.M., Smoller B., Gracely R.H., and Dubner R. Desipramine relieves postherpetic neuralgia. Clin. Pharmacol. Ther. 47 (1990) 305-312
22. Koch S., Hemrick-Luecke S.K., Thompson L.K., Evans D.C., Threlkeld P.G., Nelson D.L., Perry K.W., and Bymaster F.P. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45 (2003) 935-944
23. Lynch M.E. Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. 26 (2001) 30-36
24. Max M.B. Antidepressant Drugs as treatments for chronic pain: efficacy and mechanisms. In: Bromm B., and Desmedt J.E. (Eds). Pain and the Brain: From Nociception to Cognition. Advances in Pain Research and Therapy Vol. 22 (1995), Raven Press, New York 501-514
25. McQuay H.J., Tramer M., Nye B.A., Carroll D., Wiffen P.J., and Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain 68 (1996) 217-227
26. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 (2002) 355-474
27. Onghena P., and Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 49 (1992) 205-219
28. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283 (1997) 1305-1322
29. Rowbotham M.C., Goli V., Kunz N.R., and Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110 (2004) 697-706
30. Sawynok J., Esser M.J., and Reid A.R. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in rats. Pain 82 (1999) 149-158
31. Sindrup S.H., and Jensen T.S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83 (1999) 389-400
32. Sindrup S.H., Bjerre U., Dejgaard A., Brosen K., Eshoj O., and Mogensen E.F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42 (1990) 135-144
33. Traub R.J. Spinal modulation of the induction of central sensitization. Brain Res. 778 (1997) 34-42
34. Wong D.T., Robertson D.W., Bymaster F.P., Krushinski J.H., and Reid L.R. LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci. 43 (1988) 2049-2057
35. Wong D.T., Bymaster F.P., Mayle D.A., Reid L.R., Krushinski J.H., and Robertson D.W. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8 (1993) 23-33
36. Woolf C.J., and Doubell T.P. The pathophysiology of chronic pain-increased sensitivity to low threshold AB-fiber inputs. Curr. Opin. Neurobiol. 4 (1994) 525-534
37. Woolf C.J., Shortland P., and Sivilotti L.G. Sensitization of high mechanothreshold superficial dorsal horn and flexor motor neurones following chemosensitive primary afferent activation. Pain 58 (1994) 141-155